Meta-analysis | Included studies | Treatment | ORR | mPFS (month) | mOS (month) | SRR | Grade3/4 toxicity |
---|---|---|---|---|---|---|---|
Cremolini C [32] | CHARTA OLIVIA STEAM TRIBE TRIBE2 | bev+3-CT vs bev+2CTa | 64.5 vs 53.6% OR 1.57, P<0.001 | 12.2 vs 9,9 HR:0.74, P<0.001 | 28.9 vs 24.5 HR:0.81, P<0.001 | 16.4 vs 11.8% OR 1.48, P=0.007 | Neutropenia 45.8 vs 21.5%; P<0.001 FN 6.3 vs 3.7%; P=0.019 Diarrhea 17.8 vs 8.4%; P<0.001 |
C Bokemeyer [33] | CRYSTAL OPUS | Cet+2CT vs 2CT | 60.7 vs 40.9% OR 2.27, P <0.0001 | 10.9 vs 7.7 HR 0.64, P<0.0001 | 24.8 vs 21.1 HR 0.84, P =0.0048 | NA | NA |
F Pietrantonio [34] | Valentino TRIBE TRIBE2 STEAM CHARTA. | pan+3CT vs bev+3CT | 73 vs 77% OR 0.79, P =0.4 | 11.4 vs 13.3 HR 0.83, P =0.11 | 30.3 vs 33.1 HR 0.8, P =0.14 | 22 vs 18% P =0.51 | Neutropenia 26 vs 48%; P =0.001 Diarrhea 14 vs 6%; P =0.82 Febrile stomatitis 8 vs 6%; P =0.67 |
G Tomasello [35] | 11 studies | Bev+3CT | 69% (95%CI, 65–72%) | 12.4 (95%CI,10-14.3) | 30.2 (95%CI,26.5-33.7) | 36.6% (95%CI,24.6%-50.5%) | NA |